{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:19:04Z","timestamp":1792383544030,"version":"4.4.0"},"reference-count":174,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Pyroptosis, a lytic and inflammatory form of programmed cell death, has emerged as a regulator of tumor immunity through its capacity to trigger localized cytokine storms (operationally defined in Section 3). This review examines the dual mechanisms by which macrophage pyroptosis-driven cytokine storms influence tumor progression. Pyroptosis is executed through canonical (caspase-1\/nucleotide-binding oligomerization domain\u2013like receptor family pyrin domain\u2013containing 3 (NLRP3)\u2013dependent) and non-canonical (caspase-4\/5\/11\u2013dependent) pathways, both converging on cleavage of gasdermin D (GSDMD) to form membrane pores that release pro-inflammatory cytokines (interleukin-1 beta, IL-1\u03b2; interleukin-18, IL-18) and damage-associated molecular patterns (DAMPs). These primary signals initiate cascade amplification through chemokine and cytokine networks, recruit diverse immune cell populations, and establish distinct inflammatory microenvironments. The effects of pyroptotic cytokine storms show striking temporal and intensity dependence. Acute, moderate inflammatory responses activate anti-tumor immunity through induction of immunogenic cell death (ICD), dendritic cell maturation, and cytotoxic lymphocyte priming. Chronic, low-grade cytokine storms, in contrast, promote tumorigenesis through six interconnected mechanisms: genomic instability and epigenetic reprogramming, cancer stem cell enrichment, pro-angiogenic remodeling, pre-metastatic niche formation, establishment of an immunosuppressive microenvironment, and induction of epithelial\u2013mesenchymal transition. This \u201cdouble-edged sword\u201d phenomenon depends on inflammation intensity, duration, spatial distribution, and tumor microenvironment (TME) characteristics. Clinical investigations indicate that pyroptosis-related biomarkers, including GSDMD, gasdermin E (GSDME), and inflammatory cytokine profiles, may support patient stratification and treatment-response prediction across multiple cancer types in patients with tumor-associated macrophages (TAMs)\u2013rich tumors. Preclinical evidence from bioorthogonal chemical systems in murine models, together with mathematical modeling, has suggested that pyroptosis affecting approximately 10\u201315% of tumor cells may serve as a tentative threshold for initiating anti-tumor immunity. However, this value has been derived from a limited number of preclinical systems (primarily 4T1 mammary tumor models) and has not yet been validated in human tumors; it should therefore be interpreted as a working hypothesis rather than an established parameter. Current therapeutic strategies targeting this pathway include NLRP3 inhibitors, IL-1\u03b2\/IL-18 blockers, and combination approaches with immune checkpoint inhibitors (ICIs). Looking forward, future research should prioritize: (i) quantitative\n                    <jats:italic>in vivo<\/jats:italic>\n                    mapping of macrophage pyroptosis using spatial multi-omics and intravital imaging; (ii) development of tumor-targeted, spatiotemporally controlled pyroptosis inducers (e.g., nano-delivery and bioorthogonal activation systems); (iii) rational combination with immune checkpoint inhibitors and epigenetic modulators; and (iv) establishment of pyroptosis-based biomarker panels to guide patient stratification and toxicity prediction in clinical trials. Achieving \u201ccontrollable cytokine storms\u201d through precise macrophage pyroptosis modulation represents a therapeutic paradigm that balances anti-tumor efficacy against inflammatory toxicity, with the potential to advance cancer immunotherapy toward precision inflammation regulation.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1828486","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:13Z","timestamp":1784612113000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A double-edged sword: the role of macrophage pyroptosis-driven cytokine storm-mediated intercellular communication in tumor progression"],"prefix":"10.3389","volume":"17","author":[{"given":"Qing-feng","family":"Wang","sequence":"first","affiliation":[{"name":"Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-le","family":"Li","sequence":"additional","affiliation":[{"name":"Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-jiang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[{"name":"Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-ran","family":"Wang","sequence":"additional","affiliation":[{"name":"Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0228-2","article-title":"The gasdermins, a protein family executing cell death and inflammation","volume":"20","author":"Broz","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2016.10.004","article-title":"Pyroptosis: Gasdermin-mediated programmed necrotic cell death","volume":"42","author":"Shi","year":"2017","journal-title":"Trends Biochem Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41421-020-0167-x","article-title":"Inflammasome activation and regulation: toward a better understanding of complex mechanisms","volume":"6","author":"Zheng","year":"2020","journal-title":"Cell Discov"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2071-9","article-title":"Gasdermin E suppresses tumour growth by activating anti-tumour immunity","volume":"579","author":"Zhang","year":"2020","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1732718","article-title":"Macrophage polarization: molecular mechanisms, disease implications, and targeted therapeutic strategies","volume":"16","author":"Ji","year":"2025","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","article-title":"Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer","volume":"181","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13046-026-03676-9","article-title":"The double-edged sword role of tumor-associated macrophages: preventing or causing resistance to immunotherapy","volume":"45","author":"Roudi","year":"2026","journal-title":"J Exp Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/jci84431","article-title":"HIF1\u03b1 and metabolic reprogramming in inflammation","volume":"126","author":"Corcoran","year":"2016","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13046-021-01959-x","article-title":"Pyroptosis: a new paradigm of cell death for fighting against cancer","volume":"40","author":"Tan","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature22393","article-title":"Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin","volume":"547","author":"Wang","year":"2017","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03218-7","article-title":"NINJ1 mediates plasma membrane rupture during lytic cell death","volume":"591","author":"Kayagaki","year":"2021","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar7607","article-title":"ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation","volume":"362","author":"R\u00fchl","year":"2018","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41586-018-0372-z","article-title":"New mitochondrial DNA synthesis enables NLRP3 inflammasome activation","volume":"560","author":"Zhong","year":"2018","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.immuni.2017.11.013","article-title":"The pore-forming protein Gasdermin D regulates interleukin-1 secretion from living macrophages","volume":"48","author":"Evavold","year":"2018","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03478-3","article-title":"Gasdermin D pore structure reveals preferential release of mature interleukin-1","volume":"593","author":"Xia","year":"2021","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature13683","article-title":"Inflammatory caspases are innate immune receptors for intracellular LPS","volume":"514","author":"Shi","year":"2014","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nature15541","article-title":"Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling","volume":"526","author":"Kayagaki","year":"2015","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201545772","article-title":"Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux","volume":"45","author":"R\u00fchl","year":"2015","journal-title":"Eur J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1809548115","article-title":"Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection","volume":"115","author":"Sarhan","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau2818","article-title":"Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death","volume":"362","author":"Orning","year":"2018","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aar6689","article-title":"Gasdermin D plays a vital role in the generation of neutrophil extracellular traps","volume":"3","author":"Sollberger","year":"2018","journal-title":"Sci Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14128","article-title":"Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic\/pyroptotic cell death","volume":"8","author":"Rogers","year":"2017","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41419-023-06382-y","article-title":"The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles","volume":"14","author":"Hu","year":"2023","journal-title":"Cell Death Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz7548","article-title":"Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells","volume":"368","author":"Zhou","year":"2020","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","article-title":"Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species","volume":"50","author":"Zilionis","year":"2019","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/imr.12285","article-title":"NLRP3 at the interface of metabolism and inflammation","volume":"265","author":"Haneklaus","year":"2015","journal-title":"Immunol Rev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0240-6","article-title":"Efferocytosis in health and disease","volume":"20","author":"Doran","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/jci1112","article-title":"Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine\/paracrine mechanisms involving TGF-beta, PGE2, and PAF","volume":"101","author":"Fadok","year":"1998","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2016.08.064","article-title":"Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages","volume":"167","author":"Mills","year":"2016","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108105","article-title":"Non-coding RNAs: The key regulators in NLRP3 inflammasome-mediated inflammatory diseases","volume":"100","author":"Feng","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3535","article-title":"Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages","volume":"356","author":"Ip","year":"2017","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2015.139","article-title":"Gasdermin D is an executor of pyroptosis and required for interleukin-1\u03b2 secretion","volume":"25","author":"He","year":"2015","journal-title":"Cell Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2079-1","article-title":"A bioorthogonal system reveals antitumour immune function of pyroptosis","volume":"579","author":"Wang","year":"2020","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.cell.2020.05.039","article-title":"Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma","volume":"182","author":"Ji","year":"2020","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/imr.12614","article-title":"IL-1 and IL-1 regulatory pathways in cancer progression and therapy","volume":"281","author":"Mantovani","year":"2018","journal-title":"Immunol Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.3105cm1","article-title":"Interleukin-1 (IL-1) pathway","volume":"3","author":"Weber","year":"2010","journal-title":"Sci Signal"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32247-x","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00289","article-title":"Interleukin-18 and IL-18 binding protein","volume":"4","author":"Dinarello","year":"2013","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5RU0714-360RR","article-title":"Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP","volume":"97","author":"Fabbi","year":"2015","journal-title":"J Leukoc Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.3.1627","article-title":"Cutting edge: Priming of NK cells by IL-18","volume":"181","author":"Chaix","year":"2008","journal-title":"J Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-11-0993","article-title":"IL-18 induces PD-1-dependent immunosuppression in cancer","volume":"71","author":"Terme","year":"2011","journal-title":"Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-13-0568","article-title":"The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment","volume":"19","author":"Carbotti","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41568-019-0123-y","article-title":"Diverging inflammasome signals in tumorigenesis and potential targeting","volume":"19","author":"Karki","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2018.1439924","article-title":"Extracellular HMGB1 as a therapeutic target in inflammatory diseases","volume":"22","author":"Andersson","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"B58","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.2119\/molmed.2015.00087","article-title":"High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule","author":"Yang","year":"2015","journal-title":"Mol Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.78","article-title":"Discriminating self from non-self in nucleic acid sensing","volume":"16","author":"Schlee","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.imlet.2018.11.006","article-title":"Extracellular nucleotides and nucleosides as signalling molecules","volume":"205","author":"Giuliani","year":"2019","journal-title":"Immunol Lett"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3613","article-title":"Immunity, inflammation and cancer: a leading role for adenosine","volume":"13","author":"Antonioli","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1681\/asn.2015040405","article-title":"Necroinflammation in kidney disease","volume":"27","author":"Mulay","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111204200","article-title":"HSP70 as endogenous stimulus of the Toll\/interleukin-1 receptor signal pathway","volume":"277","author":"Vabulas","year":"2002","journal-title":"J Biol Chem"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01298","article-title":"S100A8\/A9 in inflammation","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: positioning cells for host defense and immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/nri3399","article-title":"Neutrophil recruitment and function in health and inflammation","volume":"13","author":"Kolaczkowska","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/292376","article-title":"The inflammatory chemokine CCL5 and cancer progression","volume":"2014","author":"Aldinucci","year":"2014","journal-title":"Mediators Inflammation"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028415","article-title":"Interleukin-6 family cytokines","volume":"10","author":"Rose-John","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"B75","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1615\/critreveukargeneexpr.v20.i2.10","article-title":"Tumor necrosis factor-\u03b1 signaling in macrophages","volume":"20","author":"Parameswaran","year":"2010","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190418","article-title":"Biology and therapeutic potential of interleukin-10","volume":"217","author":"Saraiva","year":"2020","journal-title":"J Exp Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"B80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","article-title":"The P2X7 receptor in infection and inflammation","volume":"47","author":"Di Virgilio","year":"2017","journal-title":"Immunity"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1038\/s41467-019-09753-2","article-title":"Caspase-1 initiates apoptosis in the absence of gasdermin D","volume":"10","author":"Tsuchiya","year":"2019","journal-title":"Nat Commun"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: the leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.immuni.2014.10.008","article-title":"Leukocyte migration into inflamed tissues","volume":"41","author":"Nourshargh","year":"2014","journal-title":"Immunity"},{"key":"B84","doi-asserted-by":"publisher","first-page":"361ra138","DOI":"10.1126\/scitranslmed.aag1711","article-title":"Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps","volume":"8","author":"Park","year":"2016","journal-title":"Sci Transl Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B87","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.09.001","article-title":"The role of type 1 conventional dendritic cells in cancer immunity","volume":"4","author":"B\u00f6ttcher","year":"2018","journal-title":"Trends Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.cell.2020.02.029","article-title":"SnapShot: Natural killer cells","volume":"180","author":"Crinier","year":"2020","journal-title":"Cell"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2010.02.013","article-title":"Inflammatory cytokines as a third signal for T cell activation","volume":"22","author":"Curtsinger","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.11.006","article-title":"Permeability of the endothelial barrier: Identifying and reconciling controversies","volume":"27","author":"Claesson-Welsh","year":"2021","journal-title":"Trends Mol Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.02.029","article-title":"Nonresolving inflammation","volume":"140","author":"Nathan","year":"2010","journal-title":"Cell"},{"key":"B94","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.thromres.2016.11.007","article-title":"Coagulation and sepsis","volume":"149","author":"Levi","year":"2017","journal-title":"Thromb Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nri3313","article-title":"A20: linking a complex regulator of ubiquitylation to immunity and human disease","volume":"12","author":"Ma","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/science.294.5548.1871","article-title":"Prostaglandins and leukotrienes: advances in eicosanoid biology","volume":"294","author":"Funk","year":"2001","journal-title":"Science"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1172\/jci97943","article-title":"Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"J Clin Invest"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.70","article-title":"A guide to immunometabolism for immunologists","volume":"16","author":"O'Neill","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0008-4","article-title":"Clocking in to immunity","volume":"18","author":"Scheiermann","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2010.09.006","article-title":"Oxidative stress, inflammation, and cancer: how are they linked","volume":"49","author":"Reuter","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1046","article-title":"Radical causes of cancer","volume":"3","author":"Hussain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.142","article-title":"NF-\u03baB, inflammation, immunity and cancer: coming of age","volume":"18","author":"Taniguchi","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2011.04.001","article-title":"Histone deacetylases as regulators of inflammation and immunity","volume":"32","author":"Shakespear","year":"2011","journal-title":"Trends Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-immunol-020711-075013","article-title":"microRNA regulation of inflammatory responses","volume":"30","author":"O'Connell","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1172\/jci57099","article-title":"Breast cancer stem cells, cytokine networks, and the tumor microenvironment","volume":"121","author":"Korkaya","year":"2011","journal-title":"J Clin Invest"},{"key":"B111","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.stem.2014.11.012","article-title":"Colorectal cancer stem cells: from the crypt to the clinic","volume":"15","author":"Zeuner","year":"2014","journal-title":"Cell Stem Cell"},{"key":"B112","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-1177","article-title":"Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy","volume":"6","author":"Incio","year":"2016","journal-title":"Cancer Discov"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-07-4843","article-title":"The interleukin-8 pathway in cancer","volume":"14","author":"Waugh","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006627","article-title":"Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2","volume":"2","author":"Lawler","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/nri1668","article-title":"Regulation of immune responses by L-arginine metabolism","volume":"5","author":"Bronte","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.10.032","article-title":"Regulatory T cells exhibit distinct features in human breast cancer","volume":"45","author":"Plitas","year":"2016","journal-title":"Immunity"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","article-title":"Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls","volume":"8","author":"Baud","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"key":"B128","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2018.12.001","article-title":"EMT transition states during tumor progression and metastasis","volume":"29","author":"Pastushenko","year":"2019","journal-title":"Trends Cell Biol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan","year":"2005","journal-title":"Nature"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1507","article-title":"Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis","volume":"8","author":"Hiratsuka","year":"2006","journal-title":"Nat Cell Biol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccr.2008.11.012","article-title":"Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche","volume":"15","author":"Erler","year":"2009","journal-title":"Cancer Cell"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/nature16140","article-title":"Neutrophils support lung colonization of metastasis-initiating breast cancer cells","volume":"528","author":"Wculek","year":"2015","journal-title":"Nature"},{"key":"B135","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nri3789","article-title":"Immune cell promotion of metastasis","volume":"15","author":"Kitamura","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.6","article-title":"Pre-metastatic niches: organ-specific homes for metastases","volume":"17","author":"Peinado","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7254.2008.00889.x","article-title":"Tumor necrosis factor and cancer, buddies or foes","volume":"29","author":"Wang","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.01.003","article-title":"Nitric oxide synthase in innate and adaptive immunity: an update","volume":"36","author":"Bogdan","year":"2015","journal-title":"Trends Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2465","article-title":"The TRAIL apoptotic pathway in cancer onset, progression and therapy","volume":"8","author":"Johnstone","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B140","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s1359-6101(00)00015-0","article-title":"Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu","volume":"12","author":"Nakanishi","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-006-9005-3","article-title":"TNF-alpha in promotion and progression of cancer","volume":"25","author":"Balkwill","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"B143","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatments for thrombosis","volume":"451","author":"Mackman","year":"2008","journal-title":"Nature"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01960","article-title":"Immunosenescence and inflamm-aging as two sides of the same coin: Friends or foes","volume":"8","author":"Fulop","year":"2017","journal-title":"Front Immunol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/jci45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J Clin Invest"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121498","article-title":"Pyroptosis as a double-edged sword: The pathogenic and therapeutic roles in inflammatory diseases and cancers","volume":"318","author":"Liu","year":"2023","journal-title":"Life Sci"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6634","article-title":"Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR\/Akt signaling and predicts a good prognosis in non-small cell lung cancer","volume":"40","author":"Gao","year":"2018","journal-title":"Oncol Rep"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110107","article-title":"Role of NLRP3 inflammasome in hepatocellular carcinoma: A double-edged sword","volume":"118","author":"Tang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30666","article-title":"Sorafenib induces pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma","volume":"70","author":"Hage","year":"2019","journal-title":"Hepatology"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.755384","article-title":"Deciphering the pyroptosis-related prognostic signature and immune cell infiltration characteristics of colon cancer","volume":"12","author":"Wei","year":"2021","journal-title":"Front Genet"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J Clin Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01444","article-title":"NLRP3 inflammasome activation in cancer: A double-edged sword","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Front Immunol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","article-title":"Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cancer Cell"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B162","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41573-021-00154-z","article-title":"Channelling inflammation: Gasdermins in physiology and disease","volume":"20","author":"Liu","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.06.011","article-title":"A fluorescent reporter mouse for inflammasome assembly demonstrates an important role for cell-bound and free ASC specks during in vivo infection","volume":"16","author":"Tzeng","year":"2016","journal-title":"Cell Rep"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3390\/biom13111664","article-title":"Gasdermin D: A potential new auxiliary pan-biomarker for the detection and diagnosis of diseases","volume":"13","author":"Wan","year":"2023","journal-title":"Biomolecules"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1111\/brv.12413","article-title":"The diverse origins of circulating cell-free DNA in the human body: A critical re-evaluation of the literature","volume":"93","author":"Aucamp","year":"2018","journal-title":"Biol Rev Camb Philos Soc"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31778","article-title":"The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy","volume":"125","author":"Bilen","year":"2019","journal-title":"Cancer"},{"key":"B167","doi-asserted-by":"publisher","first-page":"16717","DOI":"10.1038\/s41598-017-16955-5","article-title":"The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis","volume":"7","author":"Dolan","year":"2017","journal-title":"Sci Rep"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B170","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B171","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12943-025-02506-4","article-title":"Pyroptosis in cancer therapy: A double-edged sword for immune activation and tumor progression","volume":"24","author":"Alishvandi","year":"2025","journal-title":"Mol Cancer"},{"key":"B172","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1828486\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:16Z","timestamp":1784612116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1828486\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":174,"alternative-id":["10.3389\/fimmu.2026.1828486"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1828486","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1828486"}}